Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

Michael Birrer, MD, PhD
Published: Monday, Jun 19, 2017



Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Across all tumor types, there is a growing excitement around checkpoint inhibitors, which is the case in endometrial cancer as well, explains Birrer. There is a subset of patients with endometrial cancers that are microsatellite instability-high (MSI-H).

Recently, there was an approval for MSI-H tumors; however, there is still a study investigating what the response rate is for patients with endometrial cancer since the approval was based on very few patients, states Birrer.
 
SELECTED
LANGUAGE


Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Across all tumor types, there is a growing excitement around checkpoint inhibitors, which is the case in endometrial cancer as well, explains Birrer. There is a subset of patients with endometrial cancers that are microsatellite instability-high (MSI-H).

Recently, there was an approval for MSI-H tumors; however, there is still a study investigating what the response rate is for patients with endometrial cancer since the approval was based on very few patients, states Birrer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x